Science News
from research organizations

Promising Possibility For Treatment Of Esophageal Carcinoma

Date:
September 24, 2008
Source:
World Journal of Gastroenterology
Summary:
Lithium, an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta ) activity, has been linked to reduced tumor incidence. A research group in China investigated the effect of lithium on proliferation of esophageal cancer cells and its preliminary mechanisms, and results demonstrate a growth-inhibitory role of lithium in Eca-109 cells by the inhibition of GSK-3 beta and reduction of cyclin B1 expression, which provides the treatment for the esophageal squamous cell carcinoma with lithium.
Share:
       
FULL STORY

Recent work demonstrates that GSK-3 beta is involved in the process of tumorigenesis, and inhibition of the expression and activity of GSK-3 beta attenuates cell proliferation and causes apoptosis in colorectal, pancreatic and ovarian cancer cells.

Lithium is an existing drug for psychiatric diseases and its uptake has been linked to reduced tumor incidence compared to the general population, furthermore, lithium has been shown to be a specific and noncompetitive inhibitor of GSK-3 beta activity in vitro and in vivo.

Recent researches have proved that lithium could promote or inhibit cell cycle transition and proliferation of certain primary cultures or cell lines by inhibiting GSK-3 beta , depending on the cell type. However, whether lithium influences the growth and proliferation of esophageal cancer cells remains unknown to date.

A new research article demonstrates for the first time that lithium inhibited the proliferation of esophageal squamous cell carcinoma cells (Eca-109), which was mainly mediated by the inhibition of GSK-3 beta and reduction of cyclin B1 expression.

The authors demonstrated for the first time that lithium inhibited the proliferation of Eca-109 estimated by MTT assay and induce G2/M cell cycle arrest, which was mainly mediated by the inhibition of GSK-3beta and reduction of cyclin B1 expression. Lithium is an existing drug for psychiatric diseases and its uptake has been linked to reduced tumor incidence compared to the general population. Since the major target of lithium action has been shown to be GSK-3beta, the purpose of this study is reasonable and results are clearly demonstrated. Although further studies are required, this study indicates the novel possibility for the treatment of the esophageal squamous cell carcinoma with lithium cloride.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wang et al. Lithium inhibits proliferation of human esophageal cancer cell line Eca-109 by inducing a G2/M cell cycle arrest. World Journal of Gastroenterology, 2008; 14 (25): 3982 DOI: 10.3748/wjg.14.3982

Cite This Page:

World Journal of Gastroenterology. "Promising Possibility For Treatment Of Esophageal Carcinoma." ScienceDaily. ScienceDaily, 24 September 2008. <www.sciencedaily.com/releases/2008/09/080924111149.htm>.
World Journal of Gastroenterology. (2008, September 24). Promising Possibility For Treatment Of Esophageal Carcinoma. ScienceDaily. Retrieved May 29, 2015 from www.sciencedaily.com/releases/2008/09/080924111149.htm
World Journal of Gastroenterology. "Promising Possibility For Treatment Of Esophageal Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2008/09/080924111149.htm (accessed May 29, 2015).

Share This Page: